Bioscreen
- Company typePrivate
- Founded1982
- HeadquartersYarraville, Australia
- Headcount1–10
- GTM typeB2B
- OfferingServices
Bioscreen firmographics
Firmographics- Name
- Bioscreen
- Legal name
- Bioscreen Ltd Pty
- Website
- https://bioscreenmedical.com
- Company type
- Private
- Founded year
- 1982
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Bioscreen industry classification
Industry- Product category
- Clinical Microbiology Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)
- akta.pro secondary industries
- Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Bioscreen is headquartered
LocationHeadquarters
- HQ city
- Yarraville
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Bioscreen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain
Revenue model
- Diagnostic Testing Services: Bioscreen generates revenue through one-time test fees for the Faecal Microbial Analysis (FMA) test and Duodenal Aspirate test. Payment is required in advance of service provision. Tests are paid via Mastercard, Visa, Cheque, Money Order, or Cash. The company also offers paid consultations with Dr. Butt for practitioners at AUD $100 per session.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Faecal Microbial Analysis (FMA) Test - fee not publicly disclosed |
| One time/ perpetual license | Pay-as-you-go | Practitioner Consultation - AUD $100 |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
Bioscreen product offering
Product offeringCore offering
Bioscreen is a specialist microbiological laboratory that analyses gut microbiota for healthcare practitioners and their patients. The company's core offering is the Faecal Microbial Analysis (FMA) Test, which uses classical culture methodology (culturomics) combined with MALDI-TOF mass spectrometry to culture, quantify, and identify live bacteria from faecal samples, providing quantitative data on commensal gut bacteria. Bioscreen also offers a Duodenal Aspirate Test for analysis of the upper small intestine microbiota.
Product overview
Bioscreen is a specialist microbiological laboratory offering two diagnostic testing products. The primary product is the Faecal Microbial Analysis (FMA) Test, which analyzes gut microbiota using classical culture and MALDI-TOF mass spectrometry to identify and quantify live bacteria from faecal samples. The secondary product is the Duodenal Aspirate Test, which analyzes the microbiota of the upper small intestine. Both products are supported by a sample collection kit that patients use at home to collect and return samples via prepaid shipping. The company positions its testing as distinct from DNA-based competitors by focusing on culturing live bacteria, considered the 'Gold Standard' in microbiological testing.
Differentiator
Problem solved
Functional benefit
Products and services
- Faecal Microbial Analysis (FMA) Test Comprehensive analysis of gut microbiota from the large intestinal tract using classical culture techniques and MALDI-TOF mass spectrometry for identification. The test cultures, quantifies, and identifies live bacteria including aerobic organisms (coliforms, Enterococcus, Streptococcus), anaerobic bacteria (Bacteroides, Eubacterium, Bifidobacterium, Lactobacillus, Clostridium), and yeasts (Candida, Saccharomyces). It is offered to patients referred by registered healthcare practitioners and provides actionable clinical information for treatment decisions including dietary modification, probiotic protocols, and antimicrobial therapy.
- Duodenal Aspirate Test Analysis of the microbiota of the upper small intestine (duodenum), providing complementary testing to the FMA test for assessment of small intestinal bacterial overgrowth and upper gut microbiota composition.
Companies that use Bioscreen
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Bioscreen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Bioscreen partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights3 records
Bioscreen competitors and assessment
Company assessmentDirect peers
- Microba: Australian gut microbiome testing company using DNA sequencing to profile microbial communities from faecal samples. Direct competitor to Bioscreen in the Australian gut-microbiome diagnostic market, with overlapping practitioner referral channels and similar patient indications, but using a sequencing rather than culturing methodology.
- Viome: US-based direct-to-consumer gut microbiome testing company using metatranscriptomic sequencing plus AI analysis. Competes with Bioscreen on the same underlying use case (gut health testing) but serves customers globally via e-commerce rather than practitioner-mediated sales.
- Diagnostic Solutions Laboratory: US clinical laboratory offering GI pathogen and microbiome profiling for healthcare practitioners, including qPCR-based stool testing. Comparable to Bioscreen in serving functional and integrative medicine practitioners with stool-based diagnostics, though with a broader menu and DNA-based methods.
- Invivo Clinical: UK-based clinical laboratory offering microbiome and functional medicine testing through healthcare practitioners. Comparable to Bioscreen in practitioner-mediated gut health diagnostics with overlapping indications (IBS, SIBO, dysbiosis), though primarily serving UK/European markets.
Broad incumbents
- Genova Diagnostics: Established specialty clinical laboratory offering a wide portfolio of stool, hormone, and nutritional diagnostics through healthcare providers. Larger incumbent with overlapping GI testing menu including CDSA stool parasitology, comparable to Bioscreen's practitioner-mediated lab services but with much broader test catalog and US footprint.
- Doctor's Data: US specialty lab providing stool microbiology, toxic metals, and hormone testing to integrative and functional medicine practitioners. Comparable to Bioscreen in targeting the same practitioner channel for gut health diagnostics, but operates as an established incumbent with a much broader specialty testing menu.
- Thorne (OneGut / Microbiome): US-based health and wellness company offering microbiome testing alongside supplements, using shotgun metagenomic sequencing. Comparable to Bioscreen in providing gut microbiome insights to consumers and practitioners, but as part of a much broader nutritional supplement business.
Regional players
- Smart DNA: Australia-based gut microbiome testing company using 16S rRNA sequencing for consumers and clinicians. Regional competitor to Bioscreen in the Australian market, overlapping on practitioner-referred gut testing but with a sequencing rather than culturing methodology.
Others
- BioGaia: Swedish probiotic company developing Lactobacillus-based products with clinical evidence in gut and oral health. Adjacent to Bioscreen's practitioner channel rather than a direct competitor, as BioGaia supplies probiotics rather than diagnostic testing.
Emerging players
- CosmosID: Microbiome genomics company offering sequencing-based characterization of microbial communities for clinical and industrial customers. Comparable to Bioscreen in microbiome analytical services but addresses research, industrial, and clinical customers with sequencing platforms rather than culturomics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bioscreen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioscreen leadership team
Management profileNumber of profiles
Profiles3 records
Bioscreen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioscreen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioscreen
What does Bioscreen do?
Bioscreen is a specialist microbiological laboratory that analyses gut microbiota for healthcare practitioners and their patients. The company's core offering is the Faecal Microbial Analysis (FMA) Test, which uses classical culture methodology (culturomics) combined with MALDI-TOF mass spectrometry to culture, quantify, and identify live bacteria from faecal samples, providing quantitative data on commensal gut bacteria. Bioscreen also offers a Duodenal Aspirate Test for analysis of the upper small intestine microbiota.
Is Bioscreen a public or private company?
Bioscreen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bioscreen founded?
Bioscreen was founded in 1982. It employs 1 to 10 people.
Where is Bioscreen based?
Bioscreen is headquartered in Yarraville, Australia, in the Oceania region.
How does Bioscreen make money?
One revenue line is on record: diagnostic Testing Services.
Who are Bioscreen's main competitors?
Direct peers on record are Microba, Viome, Diagnostic Solutions Laboratory and Invivo Clinical. Broad incumbents are Genova Diagnostics, Doctor's Data and Thorne (OneGut / Microbiome). Smart DNA is listed as a regional player. BioGaia is listed as an others. CosmosID is listed as an emerging player.
Does Bioscreen have an API?
No public API is recorded for Bioscreen.
What industry is Bioscreen in?
Bioscreen's product category is Clinical Microbiology Laboratory Services. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal), with a secondary code of HLAFAMAD, Microbiology & Infectious Disease Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.